First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
| Primer Autor |
Shitara, Kohei
|
| Título |
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
|
| Editorial |
ELSEVIER SCIENCE INC
|
| Revista |
LANCET
|
| Lenguaje |
en
|
| Tipo de Recurso |
artículo original
|
| Derecho de Acceso |
metadata
|
| Description |
This study was supported by Bristol Myers Squibb and Ono Pharmaceutical Co. We thank the patients and their families for making the study possible and the investigators and the clinical study teams at Bristol Myers Squibb (Princeton, NJ, USA) and Ono Pharmaceutical Co (Osaka, Japan). From Bristol Myers Squibb we thank protocol managers Maria Kistkina and Charlotte Corbisier. Analysis of patient-reported outcomes was supported by Steven Blum (Bristol Myers Squibb), and Lawrence Rasouliyan and David McSorley (RTI Health Solutions, Research Triangle Park, NC, USA). Dako (Santa Clara, CA, USA) participated in collaborative development of the PD-L1 immunohistochemistry 28-8 pharmDx assay. Professional medical writing assistance was provided by Tanmayi Mankame of Parexel International, funded by Bristol Myers Squibb.
|
| doi |
10.1016/S0140-6736(21)00797-2
|
| Formato Recurso |
pdf
|
| Ubicación del archivo | |
| Categoría OCDE |
Medicina general e interna
|
| Disciplinas de la OCDE |
Medicina General e Interna
|
| Id de Web of Science |
WOS:000668969500027
|
| Access Rights |
metadata
|
| Derechos de acceso |
metadata
|
| Título de la cita (Recomendado-único) |
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
|
| Identificador del recurso (Mandatado-único) |
artículo original
|
| Versión del recurso (Recomendado-único) |
version publicada
|
| Editorial |
ELSEVIER SCIENCE INC
|
| Revista/Libro |
LANCET
|
| Categoría WOS |
Medicina general e interna
|
| Idioma |
en
|
| ISSN |
0140-6736
|
| Descripción |
This study was supported by Bristol Myers Squibb and Ono Pharmaceutical Co. We thank the patients and their families for making the study possible and the investigators and the clinical study teams at Bristol Myers Squibb (Princeton, NJ, USA) and Ono Pharmaceutical Co (Osaka, Japan). From Bristol Myers Squibb we thank protocol managers Maria Kistkina and Charlotte Corbisier. Analysis of patient-reported outcomes was supported by Steven Blum (Bristol Myers Squibb), and Lawrence Rasouliyan and David McSorley (RTI Health Solutions, Research Triangle Park, NC, USA). Dako (Santa Clara, CA, USA) participated in collaborative development of the PD-L1 immunohistochemistry 28-8 pharmDx assay. Professional medical writing assistance was provided by Tanmayi Mankame of Parexel International, funded by Bristol Myers Squibb.
|
| Referencia del Financiador (Mandatado si es aplicable-repetible) |
Bristol Myers Squibb and Ono Pharmaceutical Co.
|
| Tipo de ruta |
hibrida
|
| Formato |
pdf
|
- Colecciones
- Colección Publicaciones Científicas
cienciaabierta.ufro.cl
ciencia.abierta@ufrontera.cl